File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ultrasound contrast agent Levovist® in colour Doppler sonography of hepatocellular carcinoma in Chinese patients

TitleUltrasound contrast agent Levovist® in colour Doppler sonography of hepatocellular carcinoma in Chinese patients
Authors
KeywordsDoppler ultrasound
Hepatocellular carcinoma
Levovist®
Safety
Tolerance
Ultrasound contrast agent
Issue Date1999
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ARA
Citation
Australasian Radiology, 1999, v. 43 n. 2, p. 156-159 How to Cite?
AbstractIn a phase IIIb clinical trial of the ultrasound contrast agent Levovist® (Schering AG, Berlin, Germany), the role of Levovist® in the management of patients with clinically suspected hepatocellular carcinoma (HCC) was evaluated and its efficacy was assessed. The assessment included the duration of diagnostically usable Doppler signal enhancement, and safety and tolerance of intravenous administration. All patients with clinically suspected hepatocellular carcinoma were referred for Doppler sonographic examination over a 5-month period and lesions with absent or suboptimal Doppler signals were included in the trial. A total of 300 mg/mL in concentration (8.5 mL) of Levovist® was administered through a peripheral vein while Doppler signal intensity in the lesion, based on a visual score, was recorded. Blood pressure and pulse were recorded before and after injection. Thirty-eight patients were examined, of which 29 were included in the trial. The lesions were subsequently proven histologically to be 19 HCC, one cholangiocarcinoma, two regeneration nodules and one colonic metastasis. For six patients in whom histological proof was not available, the diagnosis of HCC was suggested based on markedly elevated serum alpha-fetoprotein levels. All but one (96%) of the 25 HCC demonstrated increased Doppler signal after Levovist®. There were no Doppler signals before and after Levovist® injection in three non-HCC lesions (two regeneration nodules and one colonic metastasis). Two patients (6.9%) suffered minor adverse reactions of nausea and vomiting. The results show that Levovist® is safe and is able to improve lesion characterization and increase diagnostic confidence of hepatocellular carcinoma by enhancing tumour vascularization Doppler signal intensity.
Persistent Identifierhttp://hdl.handle.net/10722/150873
ISSN
2009 Impact Factor: 0.51
References

 

DC FieldValueLanguage
dc.contributor.authorKhong, PLen_HK
dc.contributor.authorChau, MTen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLeong, LLYen_HK
dc.date.accessioned2012-06-26T06:13:36Z-
dc.date.available2012-06-26T06:13:36Z-
dc.date.issued1999en_HK
dc.identifier.citationAustralasian Radiology, 1999, v. 43 n. 2, p. 156-159en_HK
dc.identifier.issn0004-8461en_HK
dc.identifier.urihttp://hdl.handle.net/10722/150873-
dc.description.abstractIn a phase IIIb clinical trial of the ultrasound contrast agent Levovist® (Schering AG, Berlin, Germany), the role of Levovist® in the management of patients with clinically suspected hepatocellular carcinoma (HCC) was evaluated and its efficacy was assessed. The assessment included the duration of diagnostically usable Doppler signal enhancement, and safety and tolerance of intravenous administration. All patients with clinically suspected hepatocellular carcinoma were referred for Doppler sonographic examination over a 5-month period and lesions with absent or suboptimal Doppler signals were included in the trial. A total of 300 mg/mL in concentration (8.5 mL) of Levovist® was administered through a peripheral vein while Doppler signal intensity in the lesion, based on a visual score, was recorded. Blood pressure and pulse were recorded before and after injection. Thirty-eight patients were examined, of which 29 were included in the trial. The lesions were subsequently proven histologically to be 19 HCC, one cholangiocarcinoma, two regeneration nodules and one colonic metastasis. For six patients in whom histological proof was not available, the diagnosis of HCC was suggested based on markedly elevated serum alpha-fetoprotein levels. All but one (96%) of the 25 HCC demonstrated increased Doppler signal after Levovist®. There were no Doppler signals before and after Levovist® injection in three non-HCC lesions (two regeneration nodules and one colonic metastasis). Two patients (6.9%) suffered minor adverse reactions of nausea and vomiting. The results show that Levovist® is safe and is able to improve lesion characterization and increase diagnostic confidence of hepatocellular carcinoma by enhancing tumour vascularization Doppler signal intensity.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ARAen_HK
dc.relation.ispartofAustralasian Radiologyen_HK
dc.subjectDoppler ultrasounden_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectLevovist®en_HK
dc.subjectSafetyen_HK
dc.subjectToleranceen_HK
dc.subjectUltrasound contrast agenten_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma, Hepatocellular - Ultrasonographyen_US
dc.subject.meshContrast Media - Administration & Dosageen_US
dc.subject.meshDiagnosis, Differentialen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver Neoplasms - Ultrasonographyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPolysaccharides - Administration & Dosageen_US
dc.subject.meshUltrasonography, Doppler, Coloren_US
dc.titleUltrasound contrast agent Levovist® in colour Doppler sonography of hepatocellular carcinoma in Chinese patientsen_HK
dc.typeArticleen_HK
dc.identifier.emailKhong, PL: plkhong@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityKhong, PL=rp00467en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1440-1673.1999.00627.xen_HK
dc.identifier.pmid10901894-
dc.identifier.scopuseid_2-s2.0-0033011623en_HK
dc.identifier.hkuros41362-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033011623&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume43en_HK
dc.identifier.issue2en_HK
dc.identifier.spage156en_HK
dc.identifier.epage159en_HK
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridKhong, PL=7006693233en_HK
dc.identifier.scopusauthoridChau, MT=7006073758en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLeong, LLY=7004323766en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats